中国国家胶质瘤登记研究(CNGR):前瞻性观察性登记研究方案
CNGR是设于北京天坛医院的前瞻性纵向观察性登记研究,连续纳入成人型弥漫性胶质瘤患者,在预设时间点采集临床、病理、影像、功能及长期随访数据并存入安全电子数据采集系统。研究方案已获北京天坛医院伦理委员会批准并在中国临床试验注册中心注册,旨在为胶质瘤全程管理提供高质量真实世界数据框架。
要点
- CNGR连续纳入成人型弥漫性胶质瘤患者,采集多维纵向真实世界数据。
- 数据由培训专员按标准化流程在预设时间点采集,多学科团队全程质控。
- 目前为单中心,但全国招募保证队列多样性和广泛适用性。
核心结论
- CNGR为胶质瘤疾病轨迹提供结构化高质量真实世界数据采集框架。
- CNGR旨在成为神经肿瘤学未来多中心研究的可扩展模型和研究基础设施。
研究设计与样本
- CNGR是前瞻性、纵向、观察性登记研究,始自北京天坛医院。
- 连续纳入成人型弥漫性胶质瘤患者,签署知情同意后入组。
- 在预设时间点采集临床、病理、影像、功能及长期随访数据。
- 数据由培训专员按标准化流程采集并记录于安全电子数据采集系统。
- 多学科团队监督数据采集与质量控制,方案获北京天坛医院伦理委员会批准并注册。
临床怎么用
- 可用于增强诊断精准性、辅助治疗决策并支持预后评估。
- 可作为转化研究、循证实践和个体化治疗策略开发的资源。
局限性
- 目前为单中心研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Gliomas present a significant public health challenge owing to their complex management and poor prognosis. Robust real-world datasets are essential for advancing glioma research and informing clinical practice. To address limitations of existing resources, we established the China National Glioma Registry (CNGR), a comprehensive, glioma-specific registry designed to systematically capture multidimensional data. METHODS: The CNGR is a prospective, longitudinal, observational registry initiated at Beijing Tiantan Hospital. Adult-type diffuse glioma patients are consecutively enrolled following informed consent. Clinical, pathological, imaging, functional, and long-term follow-up data are collected at predefined time points by trained specialists using standardized procedures and recorded in a secure electronic data capture system. All aspects of data acquisition and quality control are overseen by a dedicated multidisciplinary team to ensure accuracy, consistency, and integrity. The study protocol has been approved by the Ethics Committee of Beijing Tiantan Hospital and registered with the Chinese Clinical Trial Registry. CONCLUSION: The CNGR offers a structured framework for high-quality real-world data acquisition across the glioma disease trajectory. Although currently single-center, its nationwide recruitment ensures cohort diversity and broad applicability. The CNGR is intended to serve as a scalable model for future multi-center studies in neuro-oncology and as a robust research infrastructure to enhance diagnostic precision, inform therapeutic decision-making, and support prognostic evaluation. It is poised to become a valuable resource for translational research, evidence-based practice, and the development of personalized treatment strategies in glioma care. TRIAL REGISTRATION: Chinese Clinical Trial Registry (Clinical Trial Number: ChiCTR2400094600 , Date of Registration: 2024-12-25).
引用
- Dong J, Liu L, Zhao Z, et al. China National Glioma Registry (CNGR): protocol for a prospective observational registry study. J Neurooncol. 2025. PMID: 41247591. doi:10.1007/s11060-025-05333-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。